Ryan F. Robinson - Jan 27, 2025 Form 4 Insider Report for Tourmaline Bio, Inc. (TRML)

Role
Chief Financial Officer
Signature
/s/ Brad Middlekauff, Attorney-in-Fact
Stock symbol
TRML
Transactions as of
Jan 27, 2025
Transactions value $
$0
Form type
4
Date filed
1/29/2025, 04:23 PM
Previous filing
Jun 27, 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TRML Employee Stock Option (Right to Buy) Award $0 +58K $0.00 58K Jan 27, 2025 Common Stock 58K $17.00 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares subject to the option vest as to 25% of the shares on January 27, 2026, with the remainder vesting in 36 equal monthly installments, subject to the Reporting Person's continued service on each such vesting date.